Analytical Data
-
Gene name
PSMC2
- Application
-
Alternative Names
S7; MSS1; Mammalian Suppressor Of Sgv-1 Of Yeast; Protease 26S Subunit 7; Putative Protein Product Of Nbla10058; 26S proteasome AAA-ATPase subunit RPT1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35998
-
Expression Region
Met1~Asn433
-
Molecular Weight
52kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSMC2, also known as Proteasome 26S Subunit, ATPase 2, is a vital component of the 26S proteasome complex, which plays a crucial role in protein degradation and the regulation of various cellular processes, including the cell cycle, apoptosis, and signaling pathways. The proteasome functions by recognizing ubiquitin-tagged proteins and facilitating their ATP-dependent degradation, thereby maintaining cellular homeostasis. Research into PSMC2 has gained prominence due to its involvement in several disease states, including cancer, neurodegenerative disorders, and viral infections. It has been identified as a potential therapeutic target because of its role in regulating the turnover of both oncogenic and tumor suppressor proteins. Moreover, recent studies have shown that PSMC2 may influence the efficacy of certain chemotherapeutic agents, highlighting its importance in cancer treatment strategies. Understanding the structure and function of PSMC2, as well as its interaction with other subunits within the proteasome, is critical for developing novel interventions that could enhance the effectiveness of existing therapies or lead to the creation of new ones. Given these factors, ongoing research focuses on characterizing the recombinant PSMC2 protein to elucidate its mechanisms of action, explore its interactions with potential inhibitors, and assess its role in disease progression, which could pave the way for innovative therapeutic approaches using targeted proteasome modulation.
